Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Mar 19;11(3):168.
doi: 10.3390/toxins11030168.

Daboia (Vipera) palaestinae Envenomation in 123 Horses: Treatment and Efficacy of Antivenom Administration

Sharon Tirosh-Levy  1 , Reut Solomovich-Manor  2 , Judith Comte  3 , Israel Nissan  4 , Gila A Sutton  5 , Annie Gabay  6 , Emanuel Gazit  7 , Amir Steinman  8
Affiliations

Daboia (Vipera) palaestinae Envenomation in 123 Horses: Treatment and Efficacy of Antivenom Administration

Sharon Tirosh-Levy et al. Toxins (Basel). .

Abstract

Envenomation by venomous snakes is life threatening for horses. However, the efficacy of available treatments for this occurrence, in horses, has not yet been adequately determined. The aim of this study was to describe the treatments provided in cases of Daboia palaestinae envenomation in horses and to evaluate the safety and efficacy of antivenom administration. Data regarding 123 equine snakebite cases were collected over four years from 25 veterinarians. The majority of horses were treated with procaine-penicillin (92.7%), non-steroidal anti-inflammatory drugs (82.3%), dexamethasone (81.4%), tetanus toxoid (91.1%) and antivenom (65.3%). The time interval between treatment and either cessation or 50% reduction of local swelling was linearly associated with case fatality (p < 0.001). The overall mortality rate was 20.3%. Treatment with procaine-penicillin was significantly associated with reduced mortality (OR = 0.11). Three horse-derived antivenom products were available during the study period, of which the horses were administered different brands of varying dosages. Administration of the recommended dosage of any of the aforementioned products led to a significant decrease in mortality (p = 0.014), even in severe cases (scoring 2 or greater on the equine snakebite severity scale). No adverse reactions were reported. The results of this study show that species-specific D. palaestinae antivenom administered at the manufacturer-recommended dosage is effective in significantly reducing mortality in cases of envenomation in horses.

Keywords: Daboia palaestinae; Vipera palaestinae; antivenom; envenomation; horse; snakebite.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Frequencies of administration of different treatments following Daboia palaestinae envenomation displayed as percentage of 123 horses. [n/a = not available].
Figure 2
Figure 2
Mortality rates of horses treated with different products and dosages of antivenom following Daboia palaestinae envenomation.
Figure 3
Figure 3
Mortality rates of horses treated for Daboia palaestinae envenomation, in relation to (a) cessation of progression of clinical signs (local swelling), and (b) improvement of clinical signs (50% reduction of local swelling), as subjectively assessed by the attending veterinarian. The percentage of fatal cases within each group appears in bold above each bar.
Figure 4
Figure 4
Mortality rates of horses treated with the recommended dosage of species-specific antivenom (10 mL/1000 PD50 Vipera palaestinae antiserum or 20 mL/500 PD50 Viper-stat®) in comparison to horses receiving no antivenom, or treated with less than the recommended dose (underdose) or with a non-specific antivenom product following Daboia palaestinae envenomation. The percentage of fatal cases within each group appears in bold above each bar.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Chippaux J.P. Snake-bites: Appraisal of the global situation. Bull. World Health Organ. 1998;76:515–524. - PMC - PubMed
    1. Bentur Y., Raikhlin-Eisenkraft B., Galperin M. Evaluation of antivenom therapy in Vipera palaestinae bites. Toxicon. 2004;44:53–57. doi: 10.1016/j.toxicon.2004.04.006. - DOI - PubMed
    1. Bruchim Y. Viper Snakebites. Isr. J. Vet. Med. 2010;65:39–41.
    1. Kochva E. Venomous snakes of Israel: Ecology and snakebite. Public Health Rev. 1998;26:209–232. - PubMed
    1. Segev G., Shipov A., Klement E., Harrus S., Kass P., Aroch I. Vipera palaestinae envenomation in 327 dogs: A retrospective cohort study and analysis of risk factors for mortality. Toxicon. 2004;43:691–699. doi: 10.1016/j.toxicon.2004.03.001. - DOI - PubMed

LinkOut - more resources